A Critical Reappraisal of Haloperidol for Delirium Management in the Intensive Care Unit: Perspective from Psychiatry
Abstract
:1. Introduction
2. Delirium in the Intensive Care Setting: Pathophysiology and Contribution from Neurotransmitters
3. Methods
4. A Review of Trials Examining Haloperidol Versus Placebo for Delirium Management
5. Reappraisal of the Published Literature
6. Future Directions
7. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Maldonado, J.R. Acute Brain Failure: Pathophysiology, Diagnosis, Management, and Sequelae of Delirium. Crit. Care Clin. 2017, 33, 461–519. [Google Scholar] [CrossRef] [PubMed]
- Ouimet, S.; Kavanagh, B.P.; Gottfried, S.B.; Skrobik, Y. Incidence, risk factors and consequences of ICU delirium. Intensiv. Care Med. 2007, 33, 66–73. [Google Scholar] [CrossRef]
- Ely, E.W.; Inouye, S.K.; Bernard, G.R.; Gordon, S.; Francis, J.; May, L.; Truman, B.; Speroff, T.; Gautam, S.; Mar-golin, R.; et al. Delirium in mechanically ventilated patients: Validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA 2001, 286, 2703–2710. [Google Scholar] [CrossRef]
- Witlox, J.; Eurelings, L.S.M.; de Jonghe, J.F.M.; Kalisvaart, K.J.; Eikelenboom, P.; van Gool, W.A. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: A meta-analysis. JAMA 2010, 304, 443–451. [Google Scholar] [CrossRef]
- Langan, C.; Sarode, D.P.; Russ, T.C.; Shenkin, S.D.; Carson, A.; Maclullich, A.M.J. Psychiatric symptomatology after delirium: A systematic review. Psychogeriatrics 2017, 17, 327–335. [Google Scholar] [CrossRef]
- Goldberg, T.E.; Chen, C.; Wang, Y.; Jung, E.; Swanson, A.; Ing, C.; Garcia, P.S.; Whittington, R.A.; Moitra, V. As-sociation of Delirium With Long-term Cognitive Decline: A Meta-analysis. JAMA Neurol. 2020, 77, 1373–1381. [Google Scholar] [CrossRef] [PubMed]
- Girard, T.D.; Jackson, J.C.; Pandharipande, P.P.; Pun, B.T.; Thompson, J.L.; Shintani, A.K.; Gordon, S.M.; Canonico, A.E.; Dittus, R.S.; Bernard, G.R.; et al. Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. Crit. Care Med. 2010, 38, 1513–1520. [Google Scholar] [CrossRef] [PubMed]
- Sadlonova, M.; Duque, L.; Smith, D.; Madva, E.N.; Amonoo, H.L.; Vogelsang, J.; Staton, S.C.; von Arnim, C.A.F.; Huffman, J.C.; Celano, C.M. Pharmacologic treatment of delirium symptoms: A systematic review. Gen. Hosp. Psychiatry 2022, 79, 60–75. [Google Scholar] [CrossRef]
- Neufeld, K.J.; Yue, J.; Robinson, T.N.; Inouye, S.K.; Needham, D.M. Antipsychotic Medication for Prevention and Treatment of Delirium in Hospitalized Adults: A Systematic Review and Meta-Analysis. J. Am. Geriatr. Soc. 2016, 64, 705–714. [Google Scholar] [CrossRef] [PubMed]
- Granger, B. The discovery of haloperidol. Encephale 1999, 25, 59–66. [Google Scholar] [PubMed]
- Dudley, D.L.; Rowlett, D.B.; Loebel, P.J. Emergency use of intravenous haloperidol. Gen. Hosp. Psychiatry 1979, 1, 240–246. [Google Scholar] [CrossRef] [PubMed]
- Holley, F.O.; Magliozzi, J.R.; Stanski, D.R.; Lombrozo, L.; Hollister, L.E. Haloperidol kinetics after oral and in-travenous doses. Clin. Pharmacol. Ther. 1983, 33, 477–484. [Google Scholar] [CrossRef] [PubMed]
- Beach, S.R.; Gross, A.F.; Hartney, K.E.; Taylor, J.B.; Rundell, J.R. Intravenous haloperidol: A systematic review of side effects and recommendations for clinical use. Gen. Hosp. Psychiatry 2020, 67, 42–50. [Google Scholar] [CrossRef]
- Girard, T.D.; Exline, M.C.; Carson, S.S.; Hough, C.L.; Rock, P.; Gong, M.N.; Douglas, I.S.; Malhotra, A.; Owens, R.L.; Feinstein, D.J.; et al. Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. N. Engl. J. Med. 2018, 379, 2506–2516. [Google Scholar] [CrossRef] [PubMed]
- Andersen-Ranberg, N.C.; Poulsen, L.M.; Perner, A.; Wetterslev, J.; Estrup, S.; Hästbacka, J.; Morgan, M.; Citerio, G.; Caballero, J.; Lange, T.; et al. Haloperidol for the Treatment of Delirium in ICU Patients. N. Engl. J. Med. 2022, 387, 2425–2435. [Google Scholar] [CrossRef]
- Carayannopoulos, K.L.; Alshamsi, F.; Chaudhuri, D.; Spatafora, L.; Piticaru, J.; Campbell, K.; Alhazzani, W.; Lewis, K. Antipsychotics in the Treatment of Delirium in Critically Ill Patients: A Systematic Review and Me-ta-Analysis of Randomized Controlled Trials. Crit. Care Med. 2024, 52, 1087–1096. [Google Scholar] [CrossRef] [PubMed]
- Maldonado, J.R. Delirium pathophysiology: An updated hypothesis of the etiology of acute brain failure. Int. J. Geriatr. Psychiatry 2018, 33, 1428–1457. [Google Scholar] [CrossRef] [PubMed]
- Wilson, J.E.; Mart, M.F.; Cunningham, C.; Shehabi, Y.; Girard, T.D.; MacLullich, A.M.J.; Slooter, A.J.C.; Ely, E.W. Delirium. Nat. Rev. Dis. Prim. 2020, 6, 90. [Google Scholar] [CrossRef]
- Tilouche, N.; Hassen, M.F.; Ali, H.B.S.; Jaoued, O.; Gharbi, R.; El Atrous, S.S. Delirium in the Intensive Care Unit: Incidence, Risk Factors, and Impact on Outcome. Indian J. Crit. Care Med. 2018, 22, 144–149. [Google Scholar] [CrossRef] [PubMed]
- Stollings, J.L.; Kotfis, K.; Chanques, G.; Pun, B.T.; Pandharipande, P.P.; Ely, E.W. Delirium in critical illness: Clinical manifestations, outcomes, and management. Intensiv. Care Med. 2021, 47, 1089–1103. [Google Scholar] [CrossRef] [PubMed]
- Herridge, M.S.; Azoulay, É. Outcomes after Critical Illness. N. Engl. J. Med. 2023, 388, 913–924. [Google Scholar] [CrossRef]
- Dunne, S.S.; Coffey, J.C.; Konje, S.; Gasior, S.; Clancy, C.C.; Gulati, G.; Meagher, D.; Dunne, C.P. Biomarkers in delirium: A systematic review. J. Psychosom. Res. 2021, 147, 110530. [Google Scholar] [CrossRef] [PubMed]
- Ramírez-Bermúdez, J.; Perez-Neri, I.; Montes, S.; Nente, F.; Ramirez-Abascal, M.; Carrillo-Mezo, R.; Pé-rez-Esparza, R.; Soto-Hernandez, J.L.; Espinola-Nadurille, M.; Bayliss, L.; et al. Dopaminergic Hyperactivity in Neurological Patients with Delirium. Arch. Med. Res. 2019, 50, 477–483. [Google Scholar] [CrossRef] [PubMed]
- Hshieh, T.T.; Fong, T.G.; Marcantonio, E.R.; Inouye, S.K. Cholinergic Deficiency Hypothesis in Delirium: A Syn-thesis of Current Evidence. J. Gerontol. Ser. A 2008, 63, 764–772. [Google Scholar] [CrossRef] [PubMed]
- Figueroa-Ramos, M.I.; Arroyo-Novoa, C.M.; Lee, K.A.; Padilla, G.; Puntillo, K.A. Sleep and delirium in ICU pa-tients: A review of mechanisms and manifestations. Intensiv. Care Med. 2009, 35, 781–795. [Google Scholar] [CrossRef] [PubMed]
- Egberts, A.; Moreno-Gonzalez, R.; Alan, H.; Ziere, G.; Mattace-Raso, F.U.S. Anticholinergic Drug Burden and Delirium: A Systematic Review. J. Am. Med. Dir. Assoc. 2021, 22, 65–73.e4. [Google Scholar] [CrossRef]
- Hughes, C.G.; Boncyk, C.S.; Fedeles, B.; Pandharipande, P.P.; Chen, W.; Patel, M.B.; Brummel, N.E.; Jackson, J.C.; Raman, R.; Ely, E.W.; et al. Association between cholinesterase activity and critical illness brain dysfunction. Crit. Care 2022, 26, 377. [Google Scholar] [CrossRef] [PubMed]
- Vondeling, A.M.; Knol, W.; Egberts, T.C.G.; Slooter, A.J.C. Anticholinergic drug exposure at intensive care unit admission affects the occurrence of delirium. A prospective cohort study. Eur. J. Intern. Med. 2020, 78, 121–126. [Google Scholar] [CrossRef] [PubMed]
- Juárez Olguín, H.; Calderón Guzmán, D.; Hernández García, E.; Barragán Mejía, G. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress. Oxid. Med. Cell. Longev. 2016, 2016, 9730467. [Google Scholar] [CrossRef] [PubMed]
- Broderick, P.A.; Gibson, G.E. Dopamine and serotonin in rat striatum during in vivo hypoxic-hypoxia. Metab. Brain Dis. 1989, 4, 143–153. [Google Scholar] [CrossRef] [PubMed]
- van Munster, B.C.; de Rooij, S.E.J.A.; Yazdanpanah, M.; Tienari, P.J.; Pitkälä, K.H.; Osse, R.J.; Adamis, D.; Smit, O.; van der Steen, M.S.; van Houten, M.; et al. The association of the dopamine transporter gene and the dopamine receptor 2 gene with delirium, a meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B, 648–655. [Google Scholar] [CrossRef] [PubMed]
- Anderson, B.J.; Palakshappa, J.A.; Reilly, J.P.; Ittner, C.A.G.; Ramphal, K.; Dunn, T.; Jones, T.K.; Shashaty, M.G.S.; Kolson, D.L.; Christie, J.D.; et al. Glutamate Excitotoxicity May Play a Role in Delirium and Cognitive Impairment in Sepsis. In C53. CRITICAL CARE: DELIRIUM AND THE EXPECTED AND UNEXPECTED CONSEQUENCES OF SEDATION/ANALGESIA IN THE ICU; American Thoracic Society International Conference Abstracts; American Thoracic Society: New York, NY, USA, 2017; p. A5809. [Google Scholar] [CrossRef]
- Yasuda, Y.; Nishikimi, M.; Nishida, K.; Takahashi, K.; Numaguchi, A.; Higashi, M.; Matsui, S.; Matsuda, N. Re-lationship Between Serum Norepinephrine Levels at ICU Admission and the Risk of ICU-Acquired Delirium: Secondary Analysis of the Melatonin Evaluation of Lowered Inflammation of ICU Trial. Crit. Care Explor. 2020, 2, e0082. [Google Scholar] [CrossRef] [PubMed]
- Czempik, P.F.; Pluta, M.P.; Krzych, Ł.J. Sepsis-Associated Brain Dysfunction: A Review of Current Literature. Int. J. Environ. Res. Public Health 2020, 17, 5852. [Google Scholar] [CrossRef]
- Jiang, S.; Czuma, R.; Cohen-Oram, A.; Hartney, K.; Stern, T.A. Guanfacine for Hyperactive Delirium: A Case Series. J. Acad. Consult. Liaison Psychiatry 2021, 62, 83–88. [Google Scholar] [CrossRef]
- Jiang, S.; Hernandez, M.; Burke, H.; Spurling, B.; Czuma, R.; Varghese, R.; Cohen, A.; Hartney, K.; Sullivan, G.; Kozel, F.A.; et al. A Retrospective Analysis of Guanfacine for the Pharmacological Management of Delirium. Cureus 2023, 15, e33393. [Google Scholar] [CrossRef] [PubMed]
- Ward, P.A.; Gao, H. Sepsis, complement and the dysregulated inflammatory response. J. Cell. Mol. Med. 2009, 13, 4154–4160. [Google Scholar] [CrossRef] [PubMed]
- Aird, W.C. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003, 101, 3765–3777. [Google Scholar] [CrossRef]
- Sweeney, M.D.; Zhao, Z.; Montagne, A.; Nelson, A.R.; Zlokovic, B.V. Blood-Brain Barrier: From Physiology to Disease and Back. Physiol. Rev. 2019, 99, 21–78. [Google Scholar] [CrossRef] [PubMed]
- Burry, L.D.; Cheng, W.; Williamson, D.R.; Adhikari, N.K.; Egerod, I.; Kanji, S.; Martin, C.M.; Hutton, B.; Rose, L. Pharmacological and non-pharmacological interventions to prevent delirium in critically ill patients: A systematic review and network meta-analysis. Intensiv. Care Med. 2021, 47, 943–960. [Google Scholar] [CrossRef] [PubMed]
- Wu, Y.-C.; Tseng, P.-T.; Tu, Y.-K.; Hsu, C.-Y.; Liang, C.-S.; Yeh, T.-C.; Chen, T.-Y.; Chu, C.-S.; Matsuoka, Y.J.; Stubbs, B.; et al. Association of Delirium Response and Safety of Pharmacological Interventions for the Man-agement and Prevention of Delirium: A Network Meta-analysis. JAMA Psychiatry 2019, 76, 526–535. [Google Scholar] [CrossRef]
- Andersen-Ranberg, N.C.; Barbateskovic, M.; Perner, A.; Oxenbøll Collet, M.; Musaeus Poulsen, L.; Van Der Jagt, M.; Smit, L.; Wetterslev, J.; Mathiesen, O.; Maagaard, M. Haloperidol for the treatment of delirium in critically ill patients: An updated systematic review with meta-analysis and trial sequential analysis. Crit. Care 2023, 27, 329. [Google Scholar] [CrossRef] [PubMed]
- Early, B. ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium. Clinicaltrials.gov; 2017. Available online: https://clinicaltrials.gov/study/NCT00300391 (accessed on 8 December 2024).
- Smit, L.; Slooter, A.J.C.; Devlin, J.W.; Trogrlic, Z.; Hunfeld, N.G.M.; Osse, R.J.; Ponssen, H.H.; Brouwers, A.J.B.W.; Schoonderbeek, J.F.; Simons, K.S.; et al. Efficacy of haloperidol to decrease the burden of delirium in adult criti-cally ill patients: The EuRIDICE randomized clinical trial. Crit. Care 2023, 27, 413. [Google Scholar] [CrossRef]
- Garg, R.; Singh, V.K.; Singh, G. Comparison of Haloperidol and Quetiapine for Treatment of Delirium in Critical Illness: A Prospective Randomised Double-blind Placebo-controlled Trial. JCDR 2022, 16, UC1–UC3. [Google Scholar] [CrossRef]
- Kok, L.; Slooter, A.J.; Hillegers, M.H.; Van Dijk, D.; Veldhuijzen, D.S. Benzodiazepine Use and Neuropsychiatric Outcomes in the ICU: A Systematic Review. Crit. Care Med. 2018, 46, 1673–1680. [Google Scholar] [CrossRef] [PubMed]
- Jones, C.; Griffiths, R.D.; Humphris, G. Disturbed memory and amnesia related to intensive care. Memory 2000, 8, 79–94. [Google Scholar] [CrossRef] [PubMed]
- Costa, J.B.D.; Marcon, S.S.; Macedo, C.R.L.D.; Jorge, A.C.; Duarte, P.A.D. Sedation and memories of patients subjected to mechanical ventilation in an intensive care unit. Rev. Bras. De Ter. Intensiv. 2014, 26, 122–129. [Google Scholar] [CrossRef]
- Snyder, S.H. The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. Am. J. Psychiatry 1976, 133, 197–202. [Google Scholar] [CrossRef] [PubMed]
- Brisch, R.; Saniotis, A.; Wolf, R.; Bielau, H.; Bernstein, H.-G.; Steiner, J.; Bogerts, B.; Braun, K.; Jankowski, Z.; Kumaratilake, J.; et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspec-tive: Old fashioned, but still in vogue. Front. Psychiatry 2014, 5, 47. [Google Scholar] [CrossRef]
- Coyle, J.T.; Ruzicka, W.B.; Balu, D.T. Fifty Years of Research on Schizophrenia: The Ascendance of the Glutama-tergic Synapse. Am. J. Psychiatry 2020, 177, 1119–1128. [Google Scholar] [CrossRef]
- Trzepacz, P.T.; Franco, J.G. Invited Commentary: Conflation of Delirium and Coma as Acute Encephalopathy. J. Acad. Consult. Liaison Psychiatry 2023, 64, 262–266. [Google Scholar] [CrossRef]
- Mayr, V.D.; Dünser, M.W.; Greil, V.; Jochberger, S.; Luckner, G.; Ulmer, H.; Friesenecker, B.E.; Takala, J.; Ha-sibeder, W.R. Causes of death and determinants of outcome in critically ill patients. Crit. Care 2006, 10, R154. [Google Scholar] [CrossRef] [PubMed]
- Leucht, S.; Crippa, A.; Siafis, S.; Patel, M.X.; Orsini, N.; Davis, J.M. Dose-Response Meta-Analysis of Antipsy-chotic Drugs for Acute Schizophrenia. Am. J. Psychiatry 2020, 177, 342–353. [Google Scholar] [CrossRef] [PubMed]
- Yu, C.-L.; Carvalho, A.F.; Thompson, T.; Tsai, T.-C.; Tseng, P.-T.; Hsu, C.-W.; Hsu, T.-W.; Liang, C.-S. Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia. BMJ Ment. Health 2023, 26, e300546. [Google Scholar] [CrossRef] [PubMed]
- Kongpakwattana, K.; Sawangjit, R.; Tawankanjanachot, I.; Bell, J.S.; Hilmer, S.N.; Chaiyakunapruk, N. Pharma-cological treatments for alleviating agitation in dementia: A systematic review and network meta-analysis. Br. J. Clin. Pharmacol. 2018, 84, 1445–1456. [Google Scholar] [CrossRef]
- Metzger, E.; Friedman, R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J. Clin. Psychopharmacol. 1993, 13, 128–132. [Google Scholar] [CrossRef] [PubMed]
- Meyer-Massetti, C.; Cheng, C.M.; Sharpe, B.A.; Meier, C.R.; Guglielmo, B.J. The FDA extended warning for in-travenous haloperidol and torsades de pointes: How should institutions respond? J. Hosp. Med. 2010, 5, E8–E16. [Google Scholar] [CrossRef] [PubMed]
- Morandi, A.; Piva, S.; Ely, E.W.; Myatra, S.N.; Salluh, J.I.F.; Amare, D.; Azoulay, E.; Bellelli, G.; Csomos, A.; Fan, E.; et al. Worldwide Survey of the “Assessing Pain, Both Spontaneous Awakening and Breathing Trials, Choice of Drugs, Delirium Monitoring/Management, Early Exercise/Mobility, and Family Empowerment” (ABCDEF) Bundle. Crit. Care Med. 2017, 45, e1111–e1122. [Google Scholar] [CrossRef] [PubMed]
- Stollings, J.L.; Boncyk, C.S.; Birdrow, C.I.; Chen, W.; Raman, R.; Gupta, D.K.; Roden, D.M.; Rivera, E.L.; Maiga, A.W.; Rakhit, S.; et al. Antipsychotics and the QTc Interval During Delirium in the Intensive Care Unit: A Sec-ondary Analysis of a Randomized Clinical Trial. JAMA Netw. Open 2024, 7, e2352034. [Google Scholar] [CrossRef] [PubMed]
- Satterthwaite, T.D.; Wolf, D.H.; Rosenheck, R.A.; Gur, R.E.; Caroff, S.N. A meta-analysis of the risk of acute ex-trapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J. Clin. Psychiatry 2008, 69, 1869–1879. [Google Scholar] [CrossRef] [PubMed]
- Catalan, A.; Salazar de Pablo, G.; Aymerich, C.; Guinart, D.; Goena, J.; Madaria, L.; Pacho, M.; Alameda, L.; Garrido-Torres, N.; Pedruzo, B.; et al. “Short” Versus “Long” Duration of Untreated Psychosis in People with First-Episode Psychosis: A Systematic Review and Meta-Analysis of Baseline Status and Follow-Up Outcomes. Schizophr. Bull. 2024, sbae201. [Google Scholar] [CrossRef] [PubMed]
- Dold, M.; Samara, M.T.; Li, C.; Tardy, M.; Leucht, S. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst. Rev. 2015, 1, CD009831. [Google Scholar] [CrossRef] [PubMed]
- Trzepacz, P.T.; Mittal, D.; Torres, R.; Kanary, K.; Norton, J.; Jimerson, N. Validation of the Delirium Rating Scale-revised-98: Comparison with the delirium rating scale and the cognitive test for delirium. J. Neuropsychiatry Clin. Neurosci. 2001, 13, 229–242. [Google Scholar] [CrossRef]
- Sessler, C.N.; Gosnell, M.S.; Grap, M.J.; Brophy, G.M.; O’Neal, P.V.; Keane, K.A.; Tesoro, E.P.; Elswick, R.K. The Richmond Agitation-Sedation Scale: Validity and reliability in adult intensive care unit patients. Am. J. Respir. Crit. Care Med. 2002, 166, 1338–1344. [Google Scholar] [CrossRef]
- Bahji, A.; Bach, P.; Danilewitz, M.; Crockford, D.; El-Guebaly, N.; Devoe, D.J.; Saitz, R. Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: A systematic review and network meta-analysis. Addiction 2022, 117, 2591–2601. [Google Scholar] [CrossRef] [PubMed]
- Pandharipande, P.; Shintani, A.; Peterson, J.; Pun, B.T.; Wilkinson, G.R.; Dittus, R.S.; Bernard, G.R.; Ely, E.W. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006, 104, 21–26. [Google Scholar] [CrossRef]
- Okada, M.; Mizuno, W.; Nakarai, R.; Matada, T.; Yamawaki, H.; Hara, Y. Benzodiazepines inhibit the acetylcho-line receptor-operated potassium current (IK.ACh) by different mechanisms in guinea-pig atrial myocytes. J. Vet. Med. Sci. 2012, 74, 879–884. [Google Scholar] [CrossRef] [PubMed]
- He, M.; Zhu, Z.; Jiang, M.; Liu, X.; Wu, R.; Zhou, J.; Chen, X.; Liu, C. Risk Factors for Postanesthetic Emergence Delirium in Adults: A Systematic Review and Meta-analysis. J. Neurosurg. Anesthesiol. 2024, 36, 190–200. [Google Scholar] [CrossRef]
- Lee, S.-J.; Sung, T.-Y. Emergence agitation: Current knowledge and unresolved questions. Korean J. Anaesth. 2020, 73, 471–485. [Google Scholar] [CrossRef] [PubMed]
- Wang, E.; Belley-Côté, E.P.; Young, J.; He, H.; Saud, H.; D’Aragon, F.; Um, K.; Alhazzani, W.; Piticaru, J.; Hedden, M.; et al. Effect of perioperative benzodiazepine use on intraoperative awareness and postoperative delirium: A systematic review and meta-analysis of randomised controlled trials and observational studies. Br. J. Anesthesiol. 2023, 131, 302–313. [Google Scholar] [CrossRef] [PubMed]
- D’Andria Ursoleo, J.; Licheri, M.; Barucco, G.; Losiggio, R.; Frau, G.; Pieri, M.; Monaco, F. Remimazolam for an-esthesia and sedation in cardiac surgery and for cardiac patients undergoing non-cardiac surgery: A systemat-ic-narrative hybrid review. Minerva Anestesiol. 2024, 90, 682–693. [Google Scholar] [CrossRef]
- Ishii, K.; Kuroda, K.; Tokura, C.; Michida, M.; Sugimoto, K.; Sato, T.; Ishikawa, T.; Hagioka, S.; Manabe, N.; Kurasako, T.; et al. Current status of delirium assessment tools in the intensive care unit: A prospective multi-center observational survey. Sci. Rep. 2022, 12, 2185. [Google Scholar] [CrossRef]
- Ely, E.W.; Margolin, R.; Francis, J.; May, L.; Truman, B.; Dittus, R.; Speroff, T.; Gautam, S.; Bernard, G.R.; Inouye, S.K. Evaluation of delirium in critically ill patients: Validation of the Confusion Assessment Method for the In-tensive Care Unit (CAM-ICU). Crit. Care Med. 2001, 29, 1370–1379. [Google Scholar] [CrossRef] [PubMed]
- Nishimura, K.; Yokoyama, K.; Yamauchi, N.; Koizumi, M.; Harasawa, N.; Yasuda, T.; Mimura, C.; Igita, H.; Su-zuki, E.; Uchiide, Y.; et al. Sensitivity and specificity of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) and the Intensive Care Delirium Screening Checklist (ICDSC) for detecting post-cardiac surgery delirium: A single-center study in Japan. Heart Lung 2016, 45, 15–20. [Google Scholar] [CrossRef]
- van Eijk, M.M.; van den Boogaard, M.; van Marum, R.J.; Benner, P.; Eikelenboom, P.; Honing, M.L.; van der Hoven, B.; Horn, J.; Izaks, G.J.; Kalf, A.; et al. Routine use of the confusion assessment method for the intensive care unit: A multicenter study. Am. J. Respir. Crit. Care Med. 2011, 184, 340–344. [Google Scholar] [CrossRef]
- Bergeron, N.; Dubois, M.J.; Dumont, M.; Dial, S.; Skrobik, Y. Intensive Care Delirium Screening Checklist: Evaluation of a new screening tool. Intensiv. Care Med. 2001, 27, 859–864. [Google Scholar] [CrossRef] [PubMed]
- Alosaimi, F.D.; Alghamdi, A.; Alsuhaibani, R.; Alhammad, G.; Albatili, A.; Albatly, L.; Althomali, B.; Aljamaan, F.; Maldonado, J.R. Validation of the Stanford Proxy Test for Delirium (S-PTD) among critical and noncritical pa-tients. J. Psychosom. Res. 2018, 114, 8–14. [Google Scholar] [CrossRef]
- Regier, D.A.; Kuhl, E.A.; Kupfer, D.J. The DSM-5: Classification and criteria changes. World Psychiatry 2013, 12, 92–98. [Google Scholar] [CrossRef] [PubMed]
- Liptzin, B.; Levkoff, S.E.; Cleary, P.D.; Pilgrim, D.M.; Reilly, C.H.; Albert, M.; Wetle, T.T. An empirical study of diagnostic criteria for delirium. Am. J. Psychiatry 1991, 148, 454–457. [Google Scholar] [CrossRef] [PubMed]
- Breitbart, W.; Rosenfeld, B.; Roth, A.; Smith, M.J.; Cohen, K.; Passik, S. The Memorial Delirium Assessment Scale. J. Pain Symptom Manag. 1997, 13, 128–137. [Google Scholar] [CrossRef]
- Leucht, S.; Corves, C.; Arbter, D.; Engel, R.R.; Li, C.; Davis, J.M. Second-generation versus first-generation anti-psychotic drugs for schizophrenia: A meta-analysis. Lancet 2009, 373, 31–41. [Google Scholar] [CrossRef] [PubMed]
- Kuroki, T.; Nagao, N.; Nakahara, T. Neuropharmacology of second-generation antipsychotic drugs: A validity of the serotonin-dopamine hypothesis. Prog. Brain Res. 2008, 172, 199–212. [Google Scholar] [CrossRef] [PubMed]
- Nierenberg, A.A.; Agustini, B.; Köhler-Forsberg, O.; Cusin, C.; Katz, D.; Sylvia, L.G.; Peters, A.; Berk, M. Diag-nosis and Treatment of Bipolar Disorder: A Review. JAMA 2023, 330, 1370–1380. [Google Scholar] [CrossRef] [PubMed]
- Williams, T.; Phillips, N.J.; Stein, D.J.; Ipser, J.C. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst. Rev. 2022, 3, CD002795. [Google Scholar] [CrossRef] [PubMed]
- Kishimoto, T.; Hagi, K.; Kurokawa, S.; Kane, J.M.; Correll, C.U. Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: A systematic review and meta-analysis. Psychol. Med. 2023, 53, 4064–4082. [Google Scholar] [CrossRef] [PubMed]
- Jensen, N.H.; Rodriguiz, R.M.; Caron, M.G.; Wetsel, W.C.; Rothman, R.B.; Roth, B.L. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s an-tidepressant activity. Neuropsychopharmacology 2008, 33, 2303–2312. [Google Scholar] [CrossRef] [PubMed]
- Han, L.; McCusker, J.; Cole, M.; Abrahamowicz, M.; Primeau, F.; Elie, M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch. Intern. Med. 2001, 161, 1099–1105. [Google Scholar] [CrossRef] [PubMed]
- Trzepacz, P.T.; Lee, H.B. Have Consultation-Liaison Psychiatrists Abandoned Delirium Research? J. Acad. Consult. Liaison Psychiatry 2022, 63, 519–520. [Google Scholar] [CrossRef]
Trial/Author Name; Year of Study; Country | Study Design | Number of Patients | Demographics | Population Characteristics | Delirium Screening Tool(s) Utilized; Screening Frequency; Motoric Subtype | Haloperidol Dosing Strategy; Amount Used | Rescue Medication Available? | Duration of Study | Primary Outcomes | Secondary Outcomes | Results | Comments |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Andersen-Ranberg et al.; 2022; Denmark, Finland, Italy, United Kingdom [15] | Randomized, controlled trial, blinded, multicenter | 987 (501 haloperidol; 486 placebo) | Median age 70; 35.3% female | Inclusion: 18 years of age or older; admitted to ICU; positive delirium screening test Exclusion: Received antipsychotic in ICU; contraindication to haloperidol; use of antipsychotic before hospital admission; delirium tremens; involuntary admission to hospital; consent unavailable; language barriers, deafness, blindness | ICDSC and CAM-ICU; twice a day; 55.3% hypoactive; 44.7% hyperactive | Intravenous haloperidol 2.5 mg three times daily with as needed dosing up to a maximum of 20 mg daily; median dose of 8.3 mg per day | Yes—propofol, BZDs, alpha-2 agonists | 90 days (or discharge/death) | Number of days alive and out of the hospital at 90 days after randomization; death; length of hospital stay | Number of days alive without delirium or coma; number of days alive without mechanical ventilation; number of patients with adverse effects to haloperidol; number of patients receiving rescue medication | Primary outcome: no significant difference; secondary outcomes: no significant difference | |
EuRIDICE; 2023; Netherlands [44] | Randomized, controlled trial, blinded, multicenter | 132 (65 haloperidol; 67 placebo) | Mean age 64; 32% female | Inclusion: 18 years of age and older; admitted to ICU; positive delirium screening Exclusion: Admission to ICU for acute neurological condition; pregnancy or breast-feeding; contraindication to haloperidol; history of ventricular arrhythmia; neuroleptic malignant syndrome; parkinsonism; schizophrenia or other psychotic disorder; dementia or IQCODE ≥ 4; expected duration of ICU admission <24 h; language barriers, deafness, blindness | ICDSC and CAM-ICU; three times a day; 26% hypoactive; 69% mixed; 4.6% hyperactive | Intravenous haloperidol 2.5 mg three times a day, increased up to 5 mg three times a day if needed; median dose 0.08 mg/kg per day | Yes—propofol, BZDs, alpha-2 agonists, low-dose atypical antipsychotics | 14 days | Number of delirium and coma-free days | Number of days with delirium, coma, or agitation; need for physical restraints; presence of hallucinations; RASS scores; mobility level; sleep quality; rescue medication for hallucinations/agitation; daily study drug dose and number of days used; self-extubation rate/removal of invasive devices; adverse effects; blood pressure after first dose of study drug; daily respiratory status; time to resolution of delirium; time to readiness for discharge from ICU; 28-day mortality | Primary outcome: no significant difference. Secondary outcomes: significantly fewer patients on haloperidol received benzodiazepines; significantly (but not clinically) lower systolic/diastolic BP after first drug dose; significantly less likely to fall/step out of bed; otherwise, no significant differences | Significant reduction in intrusive memories at discharge; also examined patient and family memories/experiences, presence of PTSD/anxiety/depression/cognitive impact, quality of life at 3 and 12 months (no significant difference) |
Garg et al.; 2022; India [45] | Randomized, controlled trial, blinded, single-center | 45 (15 haloperidol; 15 placebo; 15 quetiapine) | Mean age 57.32, 46.6% female | Inclusion: 18 years of age and older; admitted to ICU; positive delirium screening Exclusion: Baseline severe cognitive impairment; pregnancy or breast-feeding; neuroleptic malignant syndrome; history of torsades de pointes; contraindication to haloperidol; ongoing use of antipsychotics; rapidly resolving organ failure; moribund patients; language barriers, deafness, blindness | CAM-ICU; twice a day; subtype N/A | Oral haloperidol via nasogastric tube up to 30 mg daily; dose halved or doubled at 12 h intervals if needed | N/A | 14 days | Number of days alive without delirium | Time to freedom from ventilation; time to ICU and hospital discharge; 30- and 90-day survival | Primary outcome: no significant difference; secondary outcomes: significant reduction in mean days to ICU discharge; otherwise, no significant differences | |
Girard; 2018; United States [14] | Randomized, controlled trial, blinded, multicenter | 566 (184 placebo; 192 haloperidol; 190 ziprasidone) | Median age 61; 44% female | Inclusion: 18 years of age or older; admitted to medical or surgical ICU with invasive or non-invasive positive pressure ventilation, vasopressors, or intra-aortic balloon pump; positive delirium screening Exclusion: Severe cognitive impairment (IQCODE ≥ 4.5); pregnancy or breast-feeding; history of torsades de pointes; QT prolongation; neuroleptic malignant syndrome; contraindication to haloperidol or ziprasidone; ongoing use of antipsychotics; moribund; rapidly resolving organ failure; incarcerated; language barriers, deafness, blindness | CAM-ICU; twice a day; 89% hypoactive; 11% hyperactive | Intravenous haloperidol 2.5 mg (or 1.25 mg if 70 or above) every 12 h. Dose doubled if remained delirious; halved if no delirium. Maximum 20 mg/day; median dose of haloperidol 11 mg ± 4.8 mg per day | Yes—open-label antipsychotics | 14 days (or ICU discharge) | Number of days alive without delirium or coma | Duration of delirium, time to freedom from ventilation, ICU discharge, ICU readmission, hospital discharge, 30/90-day survival, adverse effects | Primary outcomes: no significant difference; secondary outcomes: no significant difference | |
ORIC-I; 2017 (study terminated); United States [43] | Randomized, controlled trial, blinded, single-center | Trial terminated due to insufficient recruitment | N/A | Inclusion: 18 years of age and older; admitted to medical, surgical, trauma, or cardiothoracic ICU; mechanical ventilation; positive delirium screening Exclusion: History of schizophrenia or neurologic disease that may confound the delirium assessment; QT prolongation; Parkinson’s disease; pregnancy or breast-feeding; extubation prior to enrollment; treatment with haloperidol within 2 days of ICU admission; incarceration; language barriers, deafness, blindness | N/A | Intravenous haloperidol 5 mg every 12 h | N/A | N/A | 28-day mortality; 90-day mortality | Duration of mechanical ventilation; ICU length of stay | N/A |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jiang, S.; Gunther, M. A Critical Reappraisal of Haloperidol for Delirium Management in the Intensive Care Unit: Perspective from Psychiatry. J. Clin. Med. 2025, 14, 438. https://doi.org/10.3390/jcm14020438
Jiang S, Gunther M. A Critical Reappraisal of Haloperidol for Delirium Management in the Intensive Care Unit: Perspective from Psychiatry. Journal of Clinical Medicine. 2025; 14(2):438. https://doi.org/10.3390/jcm14020438
Chicago/Turabian StyleJiang, Shixie, and Matthew Gunther. 2025. "A Critical Reappraisal of Haloperidol for Delirium Management in the Intensive Care Unit: Perspective from Psychiatry" Journal of Clinical Medicine 14, no. 2: 438. https://doi.org/10.3390/jcm14020438
APA StyleJiang, S., & Gunther, M. (2025). A Critical Reappraisal of Haloperidol for Delirium Management in the Intensive Care Unit: Perspective from Psychiatry. Journal of Clinical Medicine, 14(2), 438. https://doi.org/10.3390/jcm14020438